ClonBio Group Limited Revenue and Competitors
Employee Data
- ClonBio Group Limited has 27 Employees.
- ClonBio Group Limited grew their employee count by 0% last year.
ClonBio Group Limited's People
Name | Title | Email/Phone |
---|
ClonBio Group Limited Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $22.1M | 50 | -29% | $325.9M | N/A |
#2 | $36.7M | 237 | N/A | N/A | N/A |
#3 | $22.5M | 145 | -1% | N/A | N/A |
#4 | $4.2M | 27 | 13% | N/A | N/A |
#5 | $7.6M | 49 | 11% | N/A | N/A |
#6 | N/A | 22 | 38% | N/A | N/A |
#7 | N/A | 27 | 0% | N/A | N/A |
What Is ClonBio Group Limited?
The Group is a market leader and large-scale producer of renewable energy and animal nutrition in Europe. ClonBio invests in biotechnology that creates commercially viable bioproducts.\n\nThe Group has developed Europe’s largest grain based biorefinery over the past decade with an investment of €250 million. Its operating subsidiary, Pannonia Bio Zrt. (www.pannoniabio.com), is situated close to its corn feedstock source in the fertile crop growing regions of Hungary. \n\nThe refining process separates the constituent elements of feed corn, namely starch, protein, fibre and oils, into raw materials for renewable bioproducts.\n\nThe biorefinery currently produces ethanol and protein enriched animal feed in volume. ClonBio also functions as an incubator for bioproducts, trialling laboratory proven concepts for their potential to achieve commercial scale. \n\nNovel bioproducts are currently being developed in nutrition, health, biochemical and energy markets in partnership with concept originators.
keywords:N/AN/A
Total Funding
27
Number of Employees
N/A
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.7M | 27 | 8% | N/A |
#2 | $5.1M | 27 | -4% | N/A |
#3 | $4.2M | 27 | 13% | N/A |
#4 | N/A | 27 | 80% | N/A |
#5 | $4.8M | 27 | 8% | N/A |